收稿日期: 2021-05-20
网络出版日期: 2022-06-28
周艺, 杨莉 . 粒细胞-巨噬细胞集落刺激因子在肿瘤免疫治疗中的作用机制及临床应用进展[J]. 诊断学理论与实践, 2021 , 20(04) : 407 -413 . DOI: 10.16150/j.1671-2870.2021.04.015
| [1] | Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics[J]. CA Cancer J Clin, 2019,69(5):363-385. |
| [2] | Paver EC, Cooper WA, Colebatch AJ, et al. Programmed death ligand-1(PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation[J]. Pathology, 2021,53(2): 141-156. |
| [3] | Xue Y, Gao S, Gou J, et al. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action[J]. Expert Opin Drug Deliv, 2021,18(2):187-203. |
| [4] | Waller EK. The Role of Sargramostim (rhGM-CSF) as Immunotherapy[J]. Oncologist, 2007,12: 22-26. |
| [5] | Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle[J]. Immunity, 2013,39(1):1-10. |
| [6] | Li J, Lee Y, Li Y, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells[J]. Immunity, 2018,48(4):773-786. |
| [7] | Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy:Mechanisms, response biomarkers, and combinations[J]. SciTransl Med, 2016,8(328):328. |
| [8] | Dai W, Qiu X, Lu C, et al. AGIG chemo-immunotherapy in patients with advanced pancreatic cancer: a single-arm, single-center, phase Ⅱ study[J]. J Clin Oncol, 2021,39(3 suppl):384-384. |
| [9] | Caraglia M, Correale P, Giannicola R, et al. GOLFIG chemo-immunotherapy in metastatic colorectal cancer patients. A critical review on a long-lasting follow-up[J]. Front Oncol, 2019,9:1102. |
| [10] | Correale P, Botta C, Rotundo MS, et al. Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase Ⅲ trial[J]. J Immunother, 2014,37(1):26-35. |
| [11] | Correale P, Cusi MG, Tsang KY, et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients[J]. J Clin Oncol, 2005,23(35):8950-8958. |
| [12] | Correale P, Tagliaferri P, Fioravanti A, et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine+ FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial)[J]. Clin Cancer Res, 2008,14(13):4192-4199. |
| [13] | Dan LU, Liu L, Sun Y, et al. The phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity[J]. Nat Immunol, 2020,21(3):287-297. |
| [14] | Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization[J]. Cell, 2018,175(2):313-326. |
| [15] | La J, Cheng D, Brophy MT, et al. Real-world outcomes for patients treated with immune checkpoint inhibitors in the veterans affairs system[J]. JCO Clin Cancer Inform, 2020,4:918-928. |
| [16] | Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2020,38(1):1-10. |
| [17] | Gurbatri CR, Lia I, Vincent R, et al. Engineered probio-tics forlocal tumor delivery of checkpoint blockade nanobodies[J]. Sci Transl Med, 2020,12(530): eaax0876. |
| [18] | Kong Y, Ma Y, Zhao X, et al. Optimizing the treatment schedule of radiotherapy combined with anti-PD-1/PD-L1 immunotherapy in metastatic cancers[J]. Front Oncol, 2021,11:638873. |
| [19] | Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in neutropenia[J]. J Immunol, 2015,195(4):1341-1349. |
| [20] | Hotchkiss RS, Opal SM, et al. Activating immunity to fight a foe -a new path[J]. N Engl J Med, 2020,382(13):1270-1272. |
| [21] | van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy[J]. Blood, 2012,119(15):3383-3393. |
| [22] | Sun L, Rautela J, Delconte RB, et al. GM-CSF quantity has a selective effect on granulocytic vs. monocytic myeloid development and function[J]. Front Immunol, 2018,9:1922. |
| [23] | Martinez M, Ono N, Planutiene M, et al. Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy[J]. Cancer Cell Int, 2012,12(1):2. |
| [24] | Li X, Guo X, Ling J, et al. Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages[J]. Nanoscale, 2021,13(9):4705-4727. |
| [25] | Umakoshi M, Takahashi S, Itoh G, et al. Macrophage-mediated transfer of cancer-derived components to stromal cells contributes to establishment of a pro-tumor microenvironment[J]. Oncogene, 2019,38(12):2162-2176. |
| [26] | Trus E, Basta S, Gee K. Who′s in charge here? Macrophage colony stimulating factor and granulocyte macrophage colony stimulating factor: Competing factors in macrophage polarization[J]. Cytokine, 2020,127:154939. |
| [27] | Cabanillas F, Cotto M, Liboy I, et al. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support[J]. Leuk Lymphoma, 2012,53(10):1929-1933. |
| [28] | Zhang Y, Xiang J, Sheng X, et al. GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization[J]. Cancer Cell Int, 2021,21(1):141. |
| [29] | Oosterling SJ, Mels AK, Geijtenbeek TB, et al. Preoperative granulocyte/macrophage colony-stimulating factor (GM-CSF) increases hepatic dendritic cell numbers and clustering with lymphocytes in colorectal cancer patients[J]. Immunobiology, 2006,211(6-8):641-649. |
| [30] | Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage Ⅲ and Ⅳ malignant melanoma using granulocyte-macrophage colony-stimulating factor[J]. J Clin Oncol, 2000,18(8):1614-1621. |
| [31] | Mole RH. Whole body irradiation; radiobiology or medicine?[J]. Br J Radiol, 1953,26(305): 234-241. |
| [32] | Goto T. Radiation as an in situ auto-vaccination: current perspectives and challenges[J]. Vaccines, 2019,7(3):100. |
| [33] | Dudek AM, Garg AD, Krysko DV, et al. Inducers of immunogenic cancer cell death[J]. Cytokine Growth Factor Rev, 2013,24(4): 319-333. |
| [34] | Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice[J]. J Clin Invest, 2010,120(3):694-705. |
| [35] | Menon H, Ramapriyan R, Cushman TR, et al. Role of radiation therapy in modulation of the tumor stroma and microenvironment[J]. Front Immunol, 2019,10:193. |
| [36] | Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial[J]. Lancet Oncol, 2015,16(7):795-803. |
| [37] | Wang Y, Zenkoh J, Gerelchuluun A, et al. Administration of dendritic cells and anti-PD-1 antibody converts X-ray irradiated tumors into effective in situ vaccines[J]. Int J Radiat Oncol Biol Phys, 2019,103(4):958-969. |
| [38] | Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity[J]. Proc Natl Acad Sci U S A, 1993,90(8):3539-3543. |
| [39] | Deng G, Hu P, Zhang J, et al. Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer[J]. Oncotarget, 2016,7(51):85142-85150. |
| [40] | Xu X, Fan M, Chen J, et al. Abscopal effect and safety of recurrent and refractory advanced malignant thymoma or thymic carcinoma treated with combined therapy of local radiotherapy and granulocyte-macrophage colony-stimulating factor[J]. Int J Radiat Oncol Biol Phys, 2019:105. |
| [41] | Liu M, Cai X, Zeng Y. The abscopal effects of the combination of radiotherapy and GM-CSF for patients with metastatic thoracic cancers[J]. J Thorac Oncol, 2019,14(10):S980. |
| [42] | Mayoux M, Roller A, Pulko V, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy[J]. Sci Transl Med, 2020,12(534):eaav7431. |
| [43] | Zhang X, Shi X, Li J, et al. PD-1 blockade overcomes adaptive immune resistance in treatment with anchored-GM-CSF bladder cancer cells vaccine[J]. J Cancer, 2018,9(23):4374-4381. |
| [44] | Yu S, Sha H, Qin X, et al. EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells[J]. Oncogene, 2020,39(13):2643-2657. |
| [45] | Miyake M, Hori S, Ohnishi S, et al. Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer[J]. Cancer Sci, 2019,110(10):3315-3327. |
| [46] | Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostimvsipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial[J]. JAMA, 2014,312(17):1744-1753. |
| [47] | Kelley R K, Mitchell E, Behr S, et al. Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses[J]. J Clin Oncol, 2018,36(15_suppl):4087-4087. |
| [48] | Kong Y, Zhao X, Zou L, et al. PD-1 inhibitor combined with radiotherapy and GM-CSF as salvage therapy in patients with chemotherapy-refractory metastatic solid tumors[J]. J Clin Oncol, 2020,38(15 suppl):e15173-e15173. |
| [49] | Snehal SP, David BM, Marisa SP, et al. Five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase Ⅱb study evaluating the reduction of recurrences using HER2/neu peptide GP2+ GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer[J]. San Antonio Breast Cancer Symposium, 2020,12:PS10-PS23. |
| [50] | Schijns VE, Pretto C, Devillers L, et al. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastomamultiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity[J]. Vaccine, 2015,33(23):2690-2696. |
| [51] | Palmer DH, Valle JW, Ma YT, et al. TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas(CT TG01-01): a single-arm, phase 1/2 trial[J]. Br J Cancer, 2020,122(7):971-977. |
/
| 〈 |
|
〉 |
